Drug Profile


Alternative Names: Doribax; Doripenem hydrate; Finibax IV Solution; S-4661

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shionogi
  • Developer Janssen Research & Development; Ortho-McNeil; Shionogi
  • Class Antibacterials; Carbapenems; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-negative infections; Gram-positive infections; Intra-abdominal infections; Meningococcal infections; Nosocomial pneumonia; Paediatric infections; Respiratory tract infections; Urinary tract infections
  • Discontinued Bacterial infections; Pneumonia

Most Recent Events

  • 12 Aug 2013 Discontinued - Phase-III for Nosocomial pneumonia in Australia, Canada, Guatemala, India, Israel, Mexico, Philippines, Russia, South Africa,Thailand, Turkey and Ukraine (IV)
  • 31 Jul 2013 Phase-III clinical trials in Intra-abdominal infections (in children and adolescents) in India prior to July 2013 (IV)
  • 30 Jun 2013 Janssen terminates phase III trial in Intra-abdominal infections (in children and adolescents) in the USA, Panama, Argentina, Brazil, Chile, Colombia, India, Latvia and Lithuania (NCT01110382)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top